Literature DB >> 36175772

[Clinical aspects and care of radiogenic treatment side effects on the eye].

Andrea M Klassen1, Michael Zimbelmann2, Sabine Lüken2, Florian Cremers3, Dirk Rades3, Argyrios Chronopoulos4, Felix Rommel2, Mahdy Ranjbar2, Salvatore Grisanti2, Vinodh Kakkassery2.   

Abstract

Malignant tumors of the eye can be successfully treated with radiotherapy, which, however, can lead to radiogenic side effects in the surrounding healthy tissues. A  distinction can be made between two forms of irradiation, external radiotherapy (teletherapy) and brachytherapy with a radiation source close to the tumor. The radiation dose is important for the occurrence of side effects. Acute damage usually results from inflammatory processes initiated at the cellular level. In contrast, late side effects are rather due to the reaction of the tissue with repair and remodeling processes . Acute side effects often resolve completely, especially under corresponding treatment, whereas late side effects tend to be irreversible. The aim of this article is to present risk factors as well as the clinical signs of periocular and ocular radiogenic side effects for the relevant tissue structures of the eye in a narrative review to facilitate ophthalmologic follow-up and, if necessary, treatment measures for these patients during everyday practice.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Aftercare; Brachytherapy; Dose dependency; Ionizing radiation; Radiation forms

Mesh:

Year:  2022        PMID: 36175772     DOI: 10.1007/s00347-022-01730-3

Source DB:  PubMed          Journal:  Ophthalmologie        ISSN: 2731-720X


  37 in total

Review 1.  Radiotherapy and cataract formation.

Authors:  Zandra K Ferrufino-Ponce; Bonnie An Henderson
Journal:  Semin Ophthalmol       Date:  2006 Jul-Sep       Impact factor: 1.975

2.  Expression of membrane-associated mucins in limbal stem cell deficiency and after transplantation of cultivated limbal epithelium.

Authors:  Mikk Pauklin; Vinodh Kakkassery; Klaus-P Steuhl; Daniel Meller
Journal:  Curr Eye Res       Date:  2009-03       Impact factor: 2.424

Review 3.  Ocular risks from orbital and periorbital radiation therapy: a critical review.

Authors:  V Swetha E Jeganathan; Andrew Wirth; Michael P MacManus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-01       Impact factor: 7.038

4.  Prevention of radiation-induced stenosis of the nasolacrimal duct.

Authors:  M D de Smet; F V Buffam; R N Fairey; N J Voss
Journal:  Can J Ophthalmol       Date:  1990-04       Impact factor: 1.882

5.  The management of total xerophthalmia.

Authors:  J E Bennett
Journal:  Arch Ophthalmol       Date:  1969-05

6.  Scleral necrosis after plaque radiotherapy of uveal melanoma: a case-control study.

Authors:  Swathi Kaliki; Carol L Shields; Duangnate Rojanaporn; Josep Badal; Laxmi Devisetty; Jacqueline Emrich; Lydia Komarnicky; Jerry A Shields
Journal:  Ophthalmology       Date:  2013-01-21       Impact factor: 12.079

7.  Surgical strategies for fornix reconstruction based on symblepharon severity.

Authors:  Ahmad Kheirkhah; Gabriela Blanco; Victoria Casas; Yasutaka Hayashida; Vadrevu K Raju; Scheffer C G Tseng
Journal:  Am J Ophthalmol       Date:  2008-06-02       Impact factor: 5.258

Review 8.  Radiotherapy for ocular tumours.

Authors:  C Stannard; W Sauerwein; G Maree; K Lecuona
Journal:  Eye (Lond)       Date:  2012-11-23       Impact factor: 3.775

Review 9.  Interventional Radiotherapy (Brachytherapy) in Eyelid and Ocular Surface Tumors: A Review for Treatment of Naïve and Recurrent Malignancies.

Authors:  Monica Maria Pagliara; Vinodh Kakkassery; Bruno Fionda; Domenico Lepore; György Kovács; Luca Tagliaferri; Maria Antonietta Blasi
Journal:  Neurosignals       Date:  2022-03-25

10.  Scleral necrosis after brachytherapy for uveal melanoma: Analysis of risk factors.

Authors:  Leyla Jabbarli; Maja Guberina; Eva Biewald; Dirk Flühs; Nika Guberina; Claudia H D Le Guin; Wolfgang Sauerwein; Norbert Bornfeld; Martin Stuschke; Nikolaos E Bechrakis
Journal:  Clin Exp Ophthalmol       Date:  2021-05-04       Impact factor: 4.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.